123 related articles for article (PubMed ID: 38086166)
21. Use and outcomes of minimally invasive hysterectomy for women with nonendometrioid endometrial cancers.
Nieto VL; Huang Y; Hou JY; Tergas AI; St Clair CM; Ananth CV; Neugut AI; Hershman DL; Wright JD
Am J Obstet Gynecol; 2018 Nov; 219(5):463.e1-463.e12. PubMed ID: 30086293
[TBL] [Abstract][Full Text] [Related]
22. Impact of different adjuvant radiotherapy modalities on women with early-stage intermediate- to high-risk endometrial cancer.
Jin M; Hou X; Sun X; Zhang Y; Hu K; Zhang F
Int J Gynecol Cancer; 2019 Oct; 29(8):1264-1270. PubMed ID: 31320487
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of brachytherapy and external beam radiation therapy for early stage, node-negative uterine carcinosarcoma.
Patel N; Hegarty SE; Cantrell LA; Mishra MV; Showalter TN
Brachytherapy; 2015; 14(5):606-12. PubMed ID: 26166579
[TBL] [Abstract][Full Text] [Related]
24. Adjuvant therapy of uterine clear cell carcinoma: a review.
Xu Y; Hanna RK; Elshaikh MA
Arch Gynecol Obstet; 2016 Mar; 293(3):485-92. PubMed ID: 26626183
[TBL] [Abstract][Full Text] [Related]
25. Survival Outcomes Improved in Contemporary Cohort of Patients With Pelvic or Abdominal Recurrence After Treatment for Stage I/II Endometrial Carcinoma.
Xu MJ; Chu C; Rubin S; Lin LL
Am J Clin Oncol; 2017 Dec; 40(6):598-604. PubMed ID: 26237194
[TBL] [Abstract][Full Text] [Related]
26. Oncological Outcomes of Stage II Endometrial Cancer: A Retrospective Analysis of 250 Cases.
Ozgul N; Boyraz G; Salman MC; Gultekin M; Yuce K; Ibrahimov A; Erturk A; Gungorduk K; Gulseren V; Sanci M; Turkmen O; Karalok A; Kimyon G; Turan T; Ozkan NT; Meydanli MM; Gungor T; Ayik H; Simsek T
Int J Gynecol Cancer; 2018 Jan; 28(1):161-167. PubMed ID: 28930810
[TBL] [Abstract][Full Text] [Related]
27. Adjuvant brachytherapy for FIGO stage I serous or clear cell endometrial cancer.
Jeans EB; Breen WG; Mullikin TC; Looker BA; Mariani A; Keeney GL; Haddock MG; Petersen IA
Int J Gynecol Cancer; 2021 Jun; 31(6):859-867. PubMed ID: 33563642
[TBL] [Abstract][Full Text] [Related]
28. An analysis of current treatment practice in uterine papillary serous and clear cell carcinoma at two high volume cancer centers.
Vogel TJ; Knickerbocker A; Shah CA; Schiff MA; Isacson C; Garcia RL; Goff BA
J Gynecol Oncol; 2015 Jan; 26(1):25-31. PubMed ID: 25376917
[TBL] [Abstract][Full Text] [Related]
29. Adenocarcinoma of the endometrium treated with combined irradiation and surgery: study of 437 patients.
Touboul E; Belkacémi Y; Buffat L; Deniaud-Alexandre E; Lefranc JP; Lhuillier P; Uzan S; Jannet D; Uzan M; Antoine M; Huart J; Ganansia V; Milliez J; Blondon J; Housset M; Schlienger M
Int J Radiat Oncol Biol Phys; 2001 May; 50(1):81-97. PubMed ID: 11316550
[TBL] [Abstract][Full Text] [Related]
30. Embryologically based radical hysterectomy as peritoneal mesometrial resection (PMMR) with pelvic and para-aortic lymphadenectomy for loco-regional tumor control in endometrial cancer: first evidence for efficacy.
Kimmig R; Iannaccone A; Aktas B; Buderath P; Heubner M
Arch Gynecol Obstet; 2016 Jul; 294(1):153-60. PubMed ID: 26596725
[TBL] [Abstract][Full Text] [Related]
31. Defining the survival benefit of adjuvant pelvic radiotherapy and chemotherapy versus chemotherapy alone in stages III-IVA endometrial carcinoma.
Xiang M; English DP; Kidd EA
Gynecol Oncol; 2019 Sep; 154(3):487-494. PubMed ID: 31257010
[TBL] [Abstract][Full Text] [Related]
32. Role of brachytherapy in stage III endometrial cancer treated with adjuvant chemotherapy: Identifying factors predictive of a survival benefit.
Xiang M; English DP; Kidd EA
Brachytherapy; 2021; 20(4):701-709. PubMed ID: 33781714
[TBL] [Abstract][Full Text] [Related]
33. Effective treatment of stage I uterine papillary serous carcinoma with high dose-rate vaginal apex radiation (192Ir) and chemotherapy.
Turner BC; Knisely JP; Kacinski BM; Haffty BG; Gumbs AA; Roberts KB; Frank AH; Peschel RE; Rutherford TJ; Edraki B; Kohorn EI; Chambers SK; Schwartz PE; Wilson LD
Int J Radiat Oncol Biol Phys; 1998 Jan; 40(1):77-84. PubMed ID: 9422561
[TBL] [Abstract][Full Text] [Related]
34. The impact of adjuvant vaginal brachytherapy in women with Stage II uterine endometrioid carcinoma: Results of a National Cancer Database analysis.
Lee JK; Ghanem AI; Modh A; Burmeister C; Mahmoud O; Maxwell GL; Elshaikh MA
Brachytherapy; 2018; 17(2):319-325. PubMed ID: 29174935
[TBL] [Abstract][Full Text] [Related]
35. Effect of surgical approach on risk of recurrence after vaginal brachytherapy in early-stage high-intermediate risk endometrial cancer.
Philp L; Tannenbaum S; Haber H; Saini A; Laurent JS; James K; Feltmate CM; Russo AL; Growdon WB
Gynecol Oncol; 2021 Feb; 160(2):389-395. PubMed ID: 33358198
[TBL] [Abstract][Full Text] [Related]
36. Impact of different adjuvant treatment approaches on survival in stage III endometrial cancer: A population-based study.
van Weelden WJ; Reijnen C; Eggink FA; Boll D; Ottevanger PB; van den Berg HA; van der Aa MA; Pijnenborg JMA
Eur J Cancer; 2020 Jul; 133():104-111. PubMed ID: 32454416
[TBL] [Abstract][Full Text] [Related]
37. Compliance with adjuvant treatment guidelines in endometrial cancer: room for improvement in high risk patients.
Eggink FA; Mom CH; Boll D; Ezendam NPM; Kruitwagen RFPM; Pijnenborg JMA; van der Aa MA; Nijman HW
Gynecol Oncol; 2017 Aug; 146(2):380-385. PubMed ID: 28552255
[TBL] [Abstract][Full Text] [Related]
38. Impact of adjuvant therapy on recurrence patterns in stage I uterine carcinosarcoma.
Matsuo K; Omatsu K; Ross MS; Johnson MS; Yunokawa M; Klobocista MM; Im DD; Bush SH; Ueda Y; Takano T; Blake EA; Hasegawa K; Baba T; Shida M; Satoh S; Yokoyama T; Machida H; Adachi S; Ikeda Y; Iwasaki K; Miyake TM; Yanai S; Nishimura M; Nagano T; Takekuma M; Takeuchi S; Pejovic T; Shahzad MM; Ueland FR; Kelley JL; Roman LD
Gynecol Oncol; 2017 Apr; 145(1):78-87. PubMed ID: 28215838
[TBL] [Abstract][Full Text] [Related]
39. The impact of age on long-term outcome in patients with endometrial cancer treated with postoperative radiation.
Jolly S; Vargas CE; Kumar T; Weiner SA; Brabbins DS; Chen PY; Floyd W; Martinez AA
Gynecol Oncol; 2006 Oct; 103(1):87-93. PubMed ID: 16545441
[TBL] [Abstract][Full Text] [Related]
40. Is adjuvant therapy necessary for stage IA and IB uterine papillary serous carcinoma and clear cell carcinoma after surgical staging?
Kwon JS; Abrams J; Sugimoto A; Carey MS
Int J Gynecol Cancer; 2008; 18(4):820-4. PubMed ID: 17892450
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
